[go: up one dir, main page]

AU2002221096A1 - Medicinal compositions improved in solublity in water - Google Patents

Medicinal compositions improved in solublity in water

Info

Publication number
AU2002221096A1
AU2002221096A1 AU2002221096A AU2109602A AU2002221096A1 AU 2002221096 A1 AU2002221096 A1 AU 2002221096A1 AU 2002221096 A AU2002221096 A AU 2002221096A AU 2109602 A AU2109602 A AU 2109602A AU 2002221096 A1 AU2002221096 A1 AU 2002221096A1
Authority
AU
Australia
Prior art keywords
solublity
water
medicinal compositions
compositions improved
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002221096A
Inventor
Yohko Akiyama
Hiroto Bando
Satoshi Iinuma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU2002221096A1 publication Critical patent/AU2002221096A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2002221096A 2000-12-11 2001-12-10 Medicinal compositions improved in solublity in water Abandoned AU2002221096A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000375601 2000-12-11
JP2000-375601 2000-12-11
PCT/JP2001/010768 WO2002048141A1 (en) 2000-12-11 2001-12-10 Medicinal compositions improved in solublity in water

Publications (1)

Publication Number Publication Date
AU2002221096A1 true AU2002221096A1 (en) 2002-06-24

Family

ID=18844590

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002221096A Abandoned AU2002221096A1 (en) 2000-12-11 2001-12-10 Medicinal compositions improved in solublity in water

Country Status (10)

Country Link
US (1) US20040058956A1 (en)
EP (1) EP1350792A1 (en)
KR (1) KR20040025880A (en)
CN (1) CN1487935A (en)
AU (1) AU2002221096A1 (en)
CA (1) CA2431319A1 (en)
HU (1) HUP0401811A2 (en)
NO (1) NO20032613L (en)
PL (1) PL362979A1 (en)
WO (1) WO2002048141A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
EP1439178A4 (en) * 2001-10-05 2005-11-16 Takeda Pharmaceutical HETEROCYCLIC COMPOUNDS, OXAZOLE DERIVATIVES, PROCESS FOR THEIR PRESENTATION AND USE THEREOF
RU2293721C2 (en) 2002-02-28 2007-02-20 Джапан Тобакко Инк. Ester compounds and their using in medicine
WO2004096281A1 (en) * 2003-04-29 2004-11-11 Kowa Co., Ltd. Composition containing medicine extremely slightly soluble in water being excellent in eluting property and method for preparation thereof
MY147403A (en) * 2003-04-29 2012-11-30 Kowa Co Composition containing medicine extremely slightly solube in water and method for preparation thereof
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
US8101774B2 (en) * 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
BRPI0516772A (en) * 2004-10-25 2008-09-23 Japan Tobacco Inc solid formulation with improved solubility and stability and method for producing said formulation
AU2005317047A1 (en) * 2004-11-05 2006-06-22 Cephalon, Inc. Cancer treatments
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP1767194A1 (en) * 2005-06-09 2007-03-28 Helm AG Process for the preparation of adsorbates of drospirenone
WO2006137595A1 (en) * 2005-06-24 2006-12-28 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for her2-expressing cancer
CA2622944A1 (en) * 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Diazine azole derivatives, their manufacture and use as pharmaceutical agents
KR100767349B1 (en) * 2006-08-01 2007-10-17 삼천당제약주식회사 Oral pharmaceutical composition containing fenofibrate and a method of manufacturing the same
TWI494133B (en) 2007-03-14 2015-08-01 Tibotec Pharm Ltd Powders for reconstitution
AR072777A1 (en) 2008-03-26 2010-09-22 Cephalon Inc SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE
JP5670335B2 (en) * 2008-09-25 2015-02-18 セファロン、インク. Bendamustine liquid formulation
BRPI1004922A2 (en) * 2009-01-15 2019-09-24 Cephalon Inc pharmaceutical composition, crystalline form of the bendamustine free base and method of treatment of chronic lymphocytic leukemia, hodgkin's disease, non-hodgkin's lymphoma, multiple myeloma or breast cancer
EP2581084A4 (en) * 2010-05-31 2014-06-25 Astellas Pharma Inc Solid dispersion comprising triazole compound
EP2642996B1 (en) 2010-11-24 2020-09-23 Melinta Subsidiary Corp. Pharmaceutical compositions
WO2013056108A2 (en) * 2011-10-14 2013-04-18 Array Biopharma Inc. Solid dispersion
CN103070828B (en) * 2011-10-26 2016-01-27 山东新时代药业有限公司 A kind of solid dispersion, tablet and preparation method thereof containing Abiraterone acetate
GB2516561B (en) * 2013-03-15 2016-03-09 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
CA2943024A1 (en) 2014-03-18 2015-09-24 Takeda Pharmaceutical Company Limited Solid dispersion

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5352617A (en) * 1976-10-25 1978-05-13 Shin Etsu Chem Co Ltd Solid drug coating composition
IT1183574B (en) * 1985-05-08 1987-10-22 Eurand Spa METHOD FOR OBTAINING A HOMOGENEOUS ETHERPORARY SUSPENSION OF MICROCAPS
WO1996019239A1 (en) * 1994-12-21 1996-06-27 Yamanouchi Pharmaceutical Co., Ltd. Solid composition with improved solubility and absorbability
DE69717831T3 (en) * 1996-07-24 2018-08-30 Celgene Corp. SUBSTITUTED 2- (2,6-DIOXOPIPERIDIN-3-YL) -PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD FOR REDUCING THE TNF-ALPHA MIRROR
EP0995435B1 (en) * 1997-05-14 2007-04-25 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility

Also Published As

Publication number Publication date
NO20032613D0 (en) 2003-06-10
CN1487935A (en) 2004-04-07
HUP0401811A2 (en) 2004-12-28
WO2002048141A1 (en) 2002-06-20
PL362979A1 (en) 2004-11-02
KR20040025880A (en) 2004-03-26
CA2431319A1 (en) 2002-06-20
NO20032613L (en) 2003-08-05
EP1350792A1 (en) 2003-10-08
US20040058956A1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
AU2002221096A1 (en) Medicinal compositions improved in solublity in water
GB2358583B (en) Pharmaceutical compositions
AU2001268659A1 (en) Water treatment compositions
AU6219601A (en) Pharmaceutical compositions
GB0009584D0 (en) Pharmaceutical compositions
AU8576801A (en) Pharmaceutical compositions
AU2002214324A1 (en) Medicinal compositions
AU2001290239A1 (en) Medicinal composition
AU1390002A (en) Pharmaceutical compositions
GB0008485D0 (en) Pharmaceutical compositions
GB0009613D0 (en) Pharmaceutical compositions
AU8254101A (en) Medicinal compositions
AU2001282541A1 (en) Medicinal compositions
GB2363073B (en) Oral rehydration formulation
GB0006380D0 (en) Polymer preparation
GB0015361D0 (en) Improvements in pharmaceutical compositions
AU2002248155A1 (en) Cleansing composition
GB0023054D0 (en) Improvements in aqueous compositions
AUPQ523300A0 (en) Improvements in water treatment compositions
GB0015360D0 (en) Improvements in pharmaceutical compositions
AUPQ991200A0 (en) Improvements in or relating to dispensers
AUPQ432199A0 (en) Improvements in water treatment compositions
AUPQ271499A0 (en) Improvements in water treatment compositions
AUPQ999300A0 (en) Improvements in water treatment
AUPQ625800A0 (en) Improvements in water treatment